Robert Drapkin, MD
Articles
Infectious Complications of Pentostatin Therapy
Julie M. Vose, MD, MBA;Fernando Cabanillas, MD;Susan O’Brien, MD;Nam Dang, MD, PhD;Robert Drapkin, MD;Francine M. Foss, MD
June 1st 2000Managing the infectious complications associated with pentostatin (Nipent), used alone or in combination with other agents in patients with low-grade lymphomas, poses a significant problem for clinicians. Since there is limited
Pentostatin and Rituximab in the Treatment of Patients With B-Cell Malignancies
June 1st 2000Both pentostatin (Nipent) and rituximab (Rituxan) have single-agent activity in B-cell malignancies, including indolent and intermediate-grade non-Hodgkin’s lymphoma (NHL). Pentostatin is also active in pretreated patients
Latest Updated Articles
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Published: November 7th 2024 | Updated: November 21st 2024
Initial Workup for a Newly Diagnosed Pancreatic Cancer Patient
Published: November 7th 2024 | Updated: November 21st 2024
Treatment Considerations for Disease Progression
Published: November 7th 2024 | Updated: November 21st 2024
Treatment Paradigm for Metastatic Pancreatic Cancer
